Dr. Mark W. Millard, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 50
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 243
Licensed in Texas since 1981, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
TX license G0775 (first issued 1981; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baylor University Medical Center Dallas, TX
- Baylor Scott & White Heart & Vascular Hospital - Dallas Dallas, TX
Medical groups
- Healthtexas Provider Network (2,697 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 243
- Services billed
- 828
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 235 | 161 |
| Established patient office or other outpatient visit, 30-39 minutes | 213 | 154 |
| Test to examine how well the lungs exchange gases | 80 | 68 |
| Test for exercise-induced lung stress | 52 | 39 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 51 | 48 |
| Test to determine lung volumes using sensors | 35 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 29 |
| Test for exercise-induced heart and lung stress | 30 | 30 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
| Test to measure lung airway sensitivity | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Dallas, TX | 277 |
| Azelastine Hcl Other prescribers in Dallas, TX | 175 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Dallas, TX | 116 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Dallas, TX | 104 |
| Fluticasone Propionate Other prescribers in Dallas, TX | 93 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Dallas, TX | 80 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Dallas, TX | 78 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Dallas, TX | 68 |
| Prednisone Other prescribers in Dallas, TX | 62 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Dallas, TX | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 64 payments worth $1,594 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $479 |
|---|---|
| GlaxoSmithKline, LLC. | $471 |
| Insmed, Inc. | $230 |
| Genzyme Corporation | $98.11 |
| Vifor Pharma, Inc. | $57.12 |
| Genentech USA, Inc. | $51.37 |
| Grifols USA, LLC | $49.21 |
| Amgen Inc. | $41.54 |
| Food and Beverage | $1,594 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $103,786 in research payments for these studies, mostly to the institutions running them.
- The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A 52-week, randomised, double-blind, double-dummy, parallel group, mul
GlaxoSmithKline, LLC. - Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)
Prolaio, Inc. · Recruiting · NCT05678530
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.